Merck's Subcutaneous KEYTRUDA QLEX Approved In Japan For All Existing KEYTRUDA Indications

Merck's KEYTRUDA QLEX has received approval from Japan's Ministry of Health, Labor and Welfare for subcutaneous use across all existing KEYTRUDA indications. This marks it as the first and only subcutaneous immune checkpoint inhibitor in Japan, allowing administration by healthcare providers in as little as one minute. The product, branded as KEYJECT in Japan, can be administered every three weeks or every six weeks, depending on the dosage schedule.